AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18156457
Drug: Heparin-reduced group
RxNorm normalized name: Heparin group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-reduced group
Trial: 11036880
Drug: 100 microgram
RxNorm normalized name: Digoxin 100 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 microgram 1-thyroxine daily (Thyroxine group)
Trial: 1794835
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg afloqualone
Trial: 27484286
Drug: Lantus insulin
RxNorm normalized name: insulin glargine Injectable Solution [Lantus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lantus insulin glargine (IGlar)
Trial: 17570999
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of frequency doubling technology (FDT) perimetry and short-wavelength perimetry (SWAP)
Trial: 17570999
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of FDT and SWAP
Trial: 12167181
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g daily MgSO(4) infusion applied the day before surgery, just after operation, and 4 days following surgery
Trial: 12167181
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g daily MgSO(4) infusion
Trial: 7848024
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg twice daily
Trial: 2655682
Drug: Both formulations
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both formulations (CBZ-C and CBZ-CR)
Trial: 30782893
Drug: HORYZONS plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HORYZONS plus treatment as usual (TAU)
Trial: 28418763
Drug: Combined‐modality treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined‐modality treatment in HD7 (N = 627; median follow‐up, 120 months)
Trial: 25219291
Drug: Current reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current reference treatments
Trial: 23992914
Drug: Screening instrument
RxNorm normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening instrument before and at the end of radiation treatment
Trial: 17305759
Drug: True eradication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: True eradication therapy
Trial: 15242467
Drug: Bupropion SR
RxNorm normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion SR (300 mg/d)
Trial: 9018647
Drug: Methotrexate (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (single agent)
Trial: 7876405
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg orlistat three times a day at mid-meal (group A)
Trial: 7876405
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg orlistat at mid-meal and 0.5, 1, and 2 hr after mid-meal (group B)
Trial: 3422693
Drug: Ceftizoxime (1-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftizoxime (1-g single dose)
Trial: 3422693
Drug: Cefoxitin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin (3 doses of 2-g each)
Trial: 30734406
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy (CBT-A)
Trial: 27443596
Drug: 1-month P2Y12
RxNorm normalized name: moth bean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-month P2Y12 inhibitor therapy in combination with aspirin and apixaban
Trial: 27443596
Drug: 6-month P2Y12
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month P2Y12 inhibitor therapy in combination with aspirin and apixaban
Trial: 23326612
Drug: Mass antibiotic
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass antibiotic distribution (specifics not provided)
Trial: 21911317
Drug: Flecainide (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flecainide (3 mg/kg of weight, n=40)
Trial: 21911317
Drug: Amiodarone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (30 mg/kg weight, n=40)
Trial: 21911317
Drug: Propafenone (8.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone (8.5 mg/kg of weight, n=40)
Trial: 15727424
Drug: Chloroquine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine (150 mg daily starting 1 day after surgery)
Trial: 15727424
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard treatment without chloroquine)
Trial: 8817406
Drug: Salt-restriction cilazapril
RxNorm normalized name: cilazapril
DrugBank: Cilazapril (DB01340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salt-restriction cilazapril (2.5 mg daily)
Trial: 3907278
Drug: Perphenazine decanoate
RxNorm normalized name: perphenazine decanoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perphenazine decanoate (PD) 100 mg intramuscularly every two weeks
Trial: 3907278
Drug: Perphenazine enanthate
RxNorm normalized name: perphenazine enanthate
DrugBank: Perphenazine enanthate (DB14651)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perphenazine enanthate (PE) 100 mg intramuscularly every two weeks
Trial: 24762958
Drug: Molecularly targeted
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Molecularly targeted therapy based on tumour molecular profiling
Trial: 23165659
Drug: Sildenafil plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil plus testosterone (10-g transdermal gel for 14 weeks)
Trial: 20517210
Drug: Cortexin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortexin (10 mg/d intramuscular for 10 days) along with standard therapy
Trial: 10360853
Drug: Propofol 20
RxNorm normalized name: propofol 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 20 mg (P-20)
Trial: 10360853
Drug: Propofol 40
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 40 mg (P-40)
Trial: 24366930
Drug: Conventional postremission
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional postremission therapy
Trial: 22389708
Drug: Standard polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard polyethylene glycol‐based bowel cleansing preparation
Trial: 15734296
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral treatment (200 ml water + 100 mg danazol capsule + 3 x 500 mg paracetamol tablets + 2 x 500 mg sulfasalazine tablets)
Trial: 15734296
Drug: Standard +
RxNorm normalized name: Stangard
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard + lipid-rich meal treatment
Trial: 15734296
Drug: Standard +
RxNorm normalized name: Stangard
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard + 800 ml water treatment
Trial: 11788220
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of phosphorothioate-modified 15-mer antisense ODN
Trial: 10528036
Drug: Interferon gamma‐1b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon gamma‐1b plus prednisolone (200 microg of interferon gamma‐1b given three times per week subcutaneously and 7.5 mg of prednisolone daily)
Trial: 10528036
Drug: Prednisolone alone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone alone (7.5 mg daily, which could be increased to 25 to 50 mg daily)
Trial: 2373132
Drug: d-sotalol (0.25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-sotalol (0.25, 0.50, 1, 2 mg.kg‐1 i.v. and 100 mg oral dose)
Trial: 2373132
Drug: dl-sotalol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dl-sotalol (1 mg.kg‐1 i.v.)
Trial: 20032954
Drug: Lithium carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium carbonate (800 mg/day, serum lithium concentration 0.8-1.2 mmol/L)
Trial: 20032954
Drug: Valproate sodium
RxNorm normalized name: Valproate Sodium
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproate sodium (20 mg/kg/day, serum valproate concentration between 70 and 125 µg/ml)
Trial: 20032954
Drug: Lithium carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium carbonate (800 mg/day)
Trial: 20032954
Drug: Valproate sodium
RxNorm normalized name: Valproate Sodium
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproate sodium (20 mg/kg/day)
Trial: 11214780
Drug: Levosimendan (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan (0.5 mg four times daily for 9 days)
Trial: 11214780
Drug: Levosimendan (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan (0.5 mg four times daily for 9 days) + Warfarin (25 mg single dose on the fourth treatment day)
Trial: 9278211
Drug: Warfarin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (25 mg single dose)
Trial: 11214780
Drug: Levosimendan +
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan + Warfarin
Trial: 8894790
Drug: MgO 3
RxNorm normalized name: magnesium hydroxide 13.3 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MgO 3 times a day at a daily dose of 1.0 g (600 mg/day of magnesium)
Trial: 2071263
Drug: salmon calcitonin
RxNorm normalized name: Salmon calcitonin
DrugBank: Salmon calcitonin (DB00017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: salmon calcitonin (sCT) nasal spray
Trial: 6348587
Drug: Nadolol, 120
RxNorm normalized name: Nadolol, 120 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol, 120 mg daily
Trial: 6348587
Drug: Nadolol, 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol, 240 mg daily
Trial: 21551318
Drug: Lanreotide Autogel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide Autogel (LA) 60, 90, or 120 mg every 28 days
Trial: 21551318
Drug: Lanreotide Autogel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide Autogel (LA) 120 mg
Trial: 17548021
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy targeting glucose range of 5 to 7 mmol/L
Trial: 17548021
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy targeting glucose range of 8 to 10 mmol/L
Trial: 12081234
Drug: Sequential hMG-GnRH
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential hMG-GnRH method
Trial: 10443063
Drug: Losartan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (50 mg once daily, adjusted to 100 mg if necessary)
Trial: 10443063
Drug: Extended-release felodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release felodipine (5 mg once daily, adjusted to 10 mg if necessary)
Trial: 10443063
Drug: Extended-release felodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release felodipine (5 mg once daily)
Trial: 8991995
Drug: Tiaprofenic acid
RxNorm normalized name: tiaprofenic acid
DrugBank: Tiaprofenic acid (DB01600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiaprofenic acid 300 mg twice daily
Trial: 28145919
Drug: 1-minute rest
RxNorm normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1-minute rest interval (G-1 min)
Trial: 28145919
Drug: 3-minute rest
RxNorm normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-minute rest interval (G-3 min)
Trial: 25887099
Drug: Selumetinib 75mg
RxNorm normalized name: selumetinib
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selumetinib 75mg PO BID administered daily until progression or intolerance, one cycle was 28 days.
Trial: 22926324
Drug: Caffeine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (6 mL/kg)
Trial: 21487148
Drug: 4 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g/d of L-leucine
Trial: 19653973
Drug: Novo-venlafaxine XR
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novo-venlafaxine XR 75 mg
Trial: 19653973
Drug: Effexor XR
RxNorm normalized name: Effexor XR
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Effexor XR 75 mg
Trial: 19653973
Drug: Gen-citalopram 40
RxNorm normalized name: citalopram 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gen-citalopram 40 mg
Trial: 19653973
Drug: Celexa 40
RxNorm normalized name: Celexa 40mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celexa 40 mg
Trial: 15302319
Drug: Ibuprofen (antiprostaglandin)
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen (antiprostaglandin)
Trial: 9486567
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (two cycles of cisplatin, vincristine, peplomycin, with or without mitomycin C)
Trial: 9486567
Drug: Surgery with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery with or without peplomycin chemotherapy (Group A)
Trial: 9486567
Drug: Preoperative radiotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative radiotherapy with or without concomitant peplomycin chemotherapy followed by surgery (Group B)
Trial: 8018525
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (subcutaneous reservoir of rIFN-gamma injections)
Trial: 2555713
Drug: 3,4-Diaminopyridine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3,4-Diaminopyridine (up to 100 mg per day)
Trial: 28482639
Drug: Control (tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (tablet computer training) (n = 51)
Trial: 24012146
Drug: Selenium-silymarin mix
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium-silymarin mix (240μg selenium plus 570mg silymarin daily for 6 months)
Trial: 20888671
Drug: Preservative-free propofol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preservative-free propofol infusion
Trial: 16525231
Drug: Tetavax (licensed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetavax (licensed monovalent tetanus‐toxoid vaccine)
Trial: 10634404
Drug: GAD65-CAb in
RxNorm normalized name: K-CAB
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAD65-CAb in insulin-treated subjects
Trial: 10634404
Drug: GAD65-CAb in
RxNorm normalized name: K-CAB
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAD65-CAb in subjects treated with hypoglycemic agents and/or diet
Trial: 10634404
Drug: GAD65-MAb in
RxNorm normalized name: B-CELL MATURATION ANTIGEN (BCMA) CLUSTER OF DIFFERENTIATION 3 (CD3) BISPECIFIC MONOCLONAL ANTIBODY (MAB) ANTI-BCMA/ANTI-CD3 BISPECIFIC MAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAD65-MAb in subjects treated with hypoglycemic agents and/or diet
Trial: 29503112
Drug: 1 dose
RxNorm normalized name: Ribose 3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of MenACWY-TT at month 0 (ACWY_1)
Trial: 29503112
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of MenACWY-TT at month 0 and month 2 (ACWY_2)
Trial: 29503112
Drug: MenACWY-TT and
RxNorm normalized name: meningococcal conjugate quadrivalent, MenACWY-TT (MCV4)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY-TT and PCV13 co-administered at month 0 (Co-ad)
Trial: 12218423
Drug: Risperidone (0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (0.02 to 0.06 mg/kg per day)
Trial: 9832297
Drug: Dipyrone (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyrone (two 0.5-g tablets)
Trial: 8076441
Drug: Topical 2%
RxNorm normalized name: menthol topical 2% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 2% sodium fusidate ointment applied in the anterior nares and in the pericatheter skin twice daily for 5 days
Trial: 8076441
Drug: Oral ofloxacin
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ofloxacin 200 mg taken every 48 hours for 5 days
Trial: 1195474
Drug: Sulfacytine 1
RxNorm normalized name: SULFACYTINE
DrugBank: Sulfacytine (DB01298)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulfacytine 1 gm daily for 10 days
Trial: 1195474
Drug: Sulfisoxazole 4
RxNorm normalized name: sulfisoxazole 40 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfisoxazole 4 gm daily for 10 days
Trial: 27149410
Drug: Appetite-focused cognitive-behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Appetite-focused cognitive-behavioural therapy
Trial: 22539562
Drug: TEC (paclitaxel/carboplatin/epirubicin;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEC (paclitaxel/carboplatin/epirubicin; 75 mg/m2 i.v.)
Trial: 22539562
Drug: TC (paclitaxel/carboplatin;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TC (paclitaxel/carboplatin; AUC 5 and 175 mg/m2)
Trial: 15616084
Drug: 50 microg
RxNorm normalized name: Digoxin 250 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 microg of morphine
Trial: 15616084
Drug: 0.05 mL
RxNorm normalized name: xenon 0.05 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mL of saline (control group)
Trial: 10360204
Drug: Hydroxyzine (HYZ)
RxNorm normalized name: Hydroxizine
DrugBank: Hydroxyzine (DB00557)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxyzine (HYZ) 3.7 mg/kg
Trial: 10360204
Drug: Hydroxyzine (HYZ)
RxNorm normalized name: Hydroxizine
DrugBank: Hydroxyzine (DB00557)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxyzine (HYZ) 3.7 mg/kg + Metoclopramide (MTP) 5 mg
Trial: 7865500
Drug: Adjunctive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive treatment with the anticholinergic biperiden
Trial: 1827005
Drug: Isradipine 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine 1.25 mg or 2.5 mg twice daily orally for one year
Trial: 1827005
Drug: Isradipine with
RxNorm normalized name: Isradipine
DrugBank: Isradipine (DB00270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isradipine with beta-blocker bopindolol
Trial: 6808225
Drug: Oral antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antibiotics (neomycin, colistin, and nystatin) in conventional ward isolation
Trial: 6808225
Drug: Strict isolation,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strict isolation, filtered air, sterilized food and oral antibiotics
Trial: 6808225
Drug: Antibiotics for
RxNorm normalized name: ANTIBIOTICS FOR TOPICAL USE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics for gut flora suppression in conventional ward isolation
Trial: 31090746
Drug: Trans-sinus implants
RxNorm normalized name: sinusitisinum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trans-sinus implants without simultaneous bone grafting (group 1, n = 16)
Trial: 31090746
Drug: Trans-sinus implants
RxNorm normalized name: sinusitisinum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trans-sinus implants with sinus elevation procedures and bone grafting (group 2, n = 16)
Trial: 31090746
Drug: Trans-sinus implants
RxNorm normalized name: sinusitisinum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trans-sinus implants without simultaneous bone grafting (group 1)
Trial: 31090746
Drug: Trans-sinus implants
RxNorm normalized name: sinusitisinum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trans-sinus implants with sinus elevation procedures and bone grafting (group 2)
Trial: 18437797
Drug: Immediate implants
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate implants
Trial: 26669545
Drug: Delayed implants
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed implants
Trial: 28294200
Drug: Maxilla implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maxilla implants
Trial: 28294200
Drug: Mandible implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandible implants
Trial: 28294200
Drug: Immediate and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate and delayed implants
Trial: 15886837
Drug: Scaling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling and teeth brushing with YAHAO toothpaste (eugenol and borax cream)
Trial: 11964594
Drug: Breathing room
RxNorm normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breathing room air at hemoglobin concentration of 5.7 +/- 0.3 g/dl
Trial: 10213010
Drug: irinotecan (350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: irinotecan (350 mg/m2 every 3 weeks)
Trial: 23379651
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) with metformin